Validation of Korean Version of the COmprehensive Score for financial Toxicity (COST) Among Breast Cancer Survivors
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Little is known about the impact of financial toxicity in disease-free breast cancer survivors. We aim to validate the COmprehensive Score for financial Toxicity in Korean (COST-K) and evaluate financial toxicity among disease-free breast cancer survivors. Materials and methods: We conducted linguistic validation following a standardized methodology recommended by Functional Assessment of Chronic Illness Therapy multilingual translation (FACITtrans). For psychometric validation, we conducted a cross-sectional survey with 4,297 disease-free breast cancer survivors at a tertiary hospital in Seoul, Korea between November 2018 and April 2019. Survivors were asked to complete the COST-K and European Organization for Research and Treatment of Cancer Quality of Life Core 30 (EORTC QLQ-C30) questionnaires. The test-retest reliability, internal consistency, and validity of the COST-K were assessed using standard scale construction techniques. Results: The COST-K demonstrated good internal consistency, with a Cronbach's α of 0.81. The test-retest analysis revealed an intraclass correlation coefficient of 0.78. The COST-K had moderate correlation (r=-0.60) with the financial difficulty item of the EORTC QLQ-C30 and week correlation with the items on acute and chronic symptom burdens (nausea/vomiting, -0.18; constipation, -0.14; diarrhea, -0.14), showing good convergent and divergent validity. The median COST-K was 27 (range, 0 to 44; mean±standard deivation [SD], 27.1±7.5) and about 30% and 5% of cancer survivors experienced mild and severe financial toxicity, respectively. Younger age, lower education, lower household income was associated with higher financial toxicity. Conclusion: The COST-K is a valid and reliable instrument for measuring financial toxicity in disease-free breast cancer survivors. Considering its impact on the health-related quality of life, more studies need to be conducted to evaluate financial toxicity in cancer survivors and design interventions.
Abstract
Purpose: Little is known about the impact of financial toxicity in disease-free breast cancer survivors. We aim to validate the COmprehensive Score for financial Toxicity in Korean (COST-K) and evaluate financial toxicity among disease-free breast cancer survivors. Materials and methods: We conducted linguistic validation following a standardized methodology recommended by Functional Assessment of Chronic Illness Therapy multilingual translation (FACITtrans). For psychometric validation, we conducted a cross-sectional survey with 4,297 disease-free breast cancer survivors at a tertiary hospital in Seoul, Korea between November 2018 and April 2019. Survivors were asked to complete the COST-K and European Organization for Research and Treatment of Cancer Quality of Life Core 30 (EORTC QLQ-C30) questionnaires. The test-retest reliability, internal consistency, and validity of the COST-K were assessed using standard scale construction techniques. Results: The COST-K demonstrated good internal consistency, with a Cronbach's α of 0.81. The test-retest analysis revealed an intraclass correlation coefficient of 0.78. The COST-K had moderate correlation (r=-0.60) with the financial difficulty item of the EORTC QLQ-C30 and week correlation with the items on acute and chronic symptom burdens (nausea/vomiting, -0.18; constipation, -0.14; diarrhea, -0.14), showing good convergent and divergent validity. The median COST-K was 27 (range, 0 to 44; mean±standard deivation [SD], 27.1±7.5) and about 30% and 5% of cancer survivors experienced mild and severe financial toxicity, respectively. Younger age, lower education, lower household income was associated with higher financial toxicity. Conclusion: The COST-K is a valid and reliable instrument for measuring financial toxicity in disease-free breast cancer survivors. Considering its impact on the health-related quality of life, more studies need to be conducted to evaluate financial toxicity in cancer survivors and design interventions.
참고문헌 (29)
- Bernard DS, "National estimates of out-of-pocket health care expenditure burdens among nonelderly adults with cancer : 2001 to 2008", J Clin Oncol, 29, pp.2821~2826 (2011)
- DavidoffAJ, "Out-of-pocket health care expenditure burden for medicare beneficiaries with cancer", Cancer, 119, pp.1257~1265 (2013)
- Guy GP Jr, "Economic burden of cancer survivorship among adults in the United States", J Clin Oncol, 31, pp.3749~3757 (2013)
- Bestvina CM, "The implications of out-of-pocket cost of cancer treatment in the USA : a critical appraisal of the literature", Future Oncol, 10, pp.2189~2199 (2014)
- Witte J, "Methods for measuring financial toxicity after cancer diagnosis and treatment : a systematic review and its implications", Ann Oncol, 30, pp.1061~1070 (2019)
- Carrera PM, "The financial burden and distress of patients with cancer : understanding and stepping-up action on the financial toxicity of cancer treatment", CA Cancer J Clin, 68, pp.153~165 (2018)
- Delgado-Guay M, "Financial distress and its associations with physical and emotional symptoms and quality of life among advanced cancer patients", Oncologist, 20, pp.1092~1098 (2015)
- de Souza JA, "The development of a financial toxicity patient-reported outcome in cancer : The COST measure", Cancer, 120, pp.3245~3253 (2014)
- de Souza JA, "Measuring financial toxicity as a clinically relevant patient-reported outcome : the validation of the COmprehensive Score for financial Toxicity(COST)", Cancer, 123, pp.476~484 (2017)
- Huntington SF, "Financial toxicity in insured patients with multiple myeloma : a cross-sectional pilot study", Lancet Haematol, 2, pp.e408~e416 (2015)
- Zafar SY, "The financial toxicity of cancer treatment : a pilot study assessing out-of-pocket expenses and the insured cancer patient’s experience", Oncologist, 18, pp.381~390 (2013)
- Allcott N, "Financial burden amongst cancer patients treated with curative intent surgery alone", Am J Surg, 218, pp.452~456 (2019)
- Altice CK, "Financial hardships experienced by cancer survivors: a systematic review", J Natl Cancer Inst, 109, pp.djw205~ (2017)
- Benedict C, "Greater financial toxicity relates to greater distress and worse quality of life among breast and gynecologic cancer survivors", Psychooncology, 31, pp.9~20 (2021)
- Mady LJ, "Understanding financial toxicity in head and neck cancer survivors", Oral Oncol, 95, pp.187~193 (2019)
- Fenn KM, "Impact of financial burden of cancer on survivors’ quality of life", J Oncol Pract, 10, pp.332~338 (2014)
- Gordon LG, "A systematic review of financial toxicity among cancer survivors : we can’t pay the co-pay", Patient, 10, pp.295~309 (2017)
- Jagsi R, "Unmet need for clinician engagement regarding financial toxicity after diagnosis of breast cancer", Cancer, 124, pp.3668~3676 (2018)
- Ursachi G, "How reliable are measurement scales? External factors with indirect influence on reliability estimators", Proc Econ Finance, 20, pp.679~686 (2015)
- Gorsuch RL, "Handbook of multivariate experimental psychology", pp.231~258 (1988), Springer
- Yun YH, "Validation of the Korean version of the EORTC QLQ-C30", Qual Life Res, 13, pp.863~868 (2004)
- Fayers P, "EORTC QLQ-C30 scoring manual" (2001), European Organization for Research and Treatment of Cancer
- De Souza JA, "Validation of a financial toxicity(FT)grading system", J Clin Oncol, 35(15_Suppl), pp.6615~ (2017)
- Rosenzweig M, "Financial toxicity among women with metastatic breast cancer", Oncol Nurs Forum, 46, pp.83~91 (2019)
- Chan RJ, "Financial toxicity and symptom burden : what is the big deal?", Support Care Cancer, 26, pp.1357~1359 (2018)
- Smith GL, "Financial burdens of cancer treatment : a systematic review of risk factors and outcomes", J Natl Compr Canc Netw, 17, pp.1184~1192 (2019)
- Azzani M, "The perceived cancer-related financial hardship among patients and their families : a systematic review", Support Care Cancer, 23, pp.889~898 (2015)
- de Souza JA, "Determinants of patient-centered financial stress in patients with locally advanced head and neck cancer", J Oncol Pract, 13, pp.e310~e318 (2017)
- Gupta D, "Perceived cancer-related financial difficulty : implications for patient satisfaction with quality of life in advanced cancer", Support Care Cancer, 15, pp.1051~1056 (2007)